First-Line TNBC Decision Aid: Sacituzumab Govitecan vs Chemotherapy

A visit-time tablet tool for newly diagnosed advanced triple-negative breast cancer patients who cannot take immunotherapy, showing the quantified choice between sacituzumab govitecan and standard chemotherapy: about 3 more months before progression and responses lasting 5 months longer, with similar response rates and severe side effects but far less need to stop treatment.